Journal of Clinical Oncology · 2023 · 34 citations · 22 references
MedicineOncologyPharmacologyChemotherapyClinical PharmacologyEndocrine PharmacotherapyBreast Cancer PharmacotherapyHormonal Cancer TherapyMedication Side Effect ManagementBreast Cancer Endocrine TherapyBreast Cancer Hormonal TherapyBreast Cancer Hormone TherapyFixed-dose DosingHormone Receptor-positive Breast Cancer TherapySide Effect Profile
PURPOSE: BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib. METHODS: Patients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived. RESULTS: Of 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months). CONCLUSION: This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome.
22
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.9K citations
Medicine, Oncology, Pharmacology +17
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fátima Cardoso, S. Kyriakides, Shinji Ohno et al. · Annals of Oncology · 2019 · 2.2K citations · Full text
Medicine, Oncology, Breast Oncology +13
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz, Masakazu Toi, Mario Campone et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Global burden of cancer attributable to high body-mass index in 2012: a population-based study
Melina Arnold, Nirmala Pandeya, Graham Byrnes et al. · The Lancet Oncology · 2014 · 993 citations · Full text
Medicine, Health Policy, Oncology +17
Gabriel N. Hortobágyi, Salomon M. Stemmer, H. A. Burris et al. · Annals of Oncology · 2018 · 868 citations · Full text
Medicine, Oncology, Pharmacology +17